Arbutus Biopharma Corp

ABUS

Arbutus Biopharma Corp

ABUS

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2025-02-04Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:138,639,956Shares Outstanding:193,768,641Institutional Ownership Pct.:71.55%

Earnings Market Reaction:

Filing Date:2026-05-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	24	18	22	37	37	36	32	63	43	26	18	27
Short Term Investments	-	73	-	-	-	86	-	-	-	100	-	-
Available For Sale Securities Debt Securities Curr…	72	-	71	61	76	-	96	79	86	-	117	125
Accounts Receivable Net Current	1	1	1	1	1	2	2	2	2	2	2	3
Accounts And Other Receivables Net Current	179	-	-	-	-	-	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	2	2	3	4	3	2	3	4	4	4	5	4
Assets Current	277	94	97	103	117	127	133	148	136	132	142	159
Property Plant And Equipment Net	0	0	0	0	0	3	4	4	4	5	5	5
Long Term Investments	-	0	-	-	-	0	3	7	9	6	10	11
Operating Lease Right Of Use Asset	-	0	0	0	0	1	1	1	1	1	2	2
Other Assets Noncurrent	0	0	0	0	0	0	-	-	-	0	0	0
Assets	277	95	98	103	117	132	140	160	150	144	159	177
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	4	5	5	5	12	8	8	11	8	10	10	9
Deferred Revenue Current	-	0	0	0	7	8	11	11	12	12	12	15
Operating Lease Liability Current	1	1	1	1	1	0	0	0	1	0	0	0
Liabilities Current	5	6	5	5	19	16	19	23	20	22	22	25
Deferred Revenue Noncurrent	-	0	0	0	3	3	-	-	-	0	0	0
Business Combination Contingent Consideration Liab…	9	8	11	11	11	10	8	8	8	8	7	7
Operating Lease Liability Noncurrent	0	0	0	1	1	1	1	1	1	1	1	2
Liabilities	17	18	20	20	38	34	34	38	36	38	39	42
Statement Of Stockholders…
Common Stock Value	1,444	1,421	1,419	1,417	1,416	1,410	1,408	1,403	1,377	1,350	1,346	1,344
Additional Paid In Capital	74	83	83	83	82	82	81	82	80	81	80	77
Retained Earnings Accumulated Deficit	-1,210	-1,380	-1,376	-1,369	-1,371	-1,347	-1,334	-1,314	-1,295	-1,277	-1,257	-1,237
Accumulated Other Comprehensive Income Loss Net Of…	-48	-48	-48	-48	-48	-48	-48	-48	-48	-48	-49	-49
Stockholders Equity	260	77	77	83	79	97	107	122	115	106	119	135
Liabilities And Stockholders Equity	277	95	98	103	117	132	140	160	150	144	159	177
Accumulated Depreciation Depletion And Amortizatio…	0	-	13	13	13	-	13	13	12	-	12	11
Common Stock Shares Issued	197	193	192	192	191	190	189	189	180	170	168	167
Shares Outstanding	197	193	192	192	191	190	189	189	180	170	168	167

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-1.39%	12.99%	-	-	-	-	-	-	-	-	-	-
2025	10.13%	2.53%	3.48%	6.92%	27.09%	25.65%	-3.07%	4.61%	-9.43%	6.79%	-4.07%	-3.62%
2024	22.76%	13.81%	37.69%	7.50%	6.39%	10.28%	-11.73%	-18.11%	-15.31%	-3.67%	-5.81%	7.95%
2023	-	-	-	-1.46%	-6.31%	-15.53%	9.73%	35.14%	28.65%	-3.37%	2.25%	23.22%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	54.26	15.73	18.80	20.53	6.01	8.15	7.02	6.56	6.69	5.87	6.34	6.47
Quick Ratio	53.92	15.47	18.25	19.74	5.86	8.01	6.84	6.36	6.47	5.68	6.11	6.32
Working Capital	271.91M	88.45M	92.26M	98.10M	97.38M	111.70M	113.85M	125.63M	115.58M	109.54M	119.28M	134.27M
Leverage & Debt
Debt to Equity	0.07	0.24	0.26	0.24	0.48	0.35	0.31	0.31	0.31	0.36	0.33	0.31
Interest Coverage TTM	1,819.15	-393.40	-429.39	-518.12	-683.10	-557.07	-550.55	-495.54	-262.47	-170.16	-110.38	-68.81
Debt Ratio	0.06	0.19	0.21	0.20	0.32	0.26	0.24	0.23	0.24	0.27	0.25	0.24
Efficiency & Turnover
Asset Turnover TTM	0.97	0.12	0.12	0.12	0.05	0.04	0.05	0.06	0.08	0.11	0.12	0.12
Days Sales Outstanding TTM	2.38	49.97	31.40	33.05	94.66	123.77	102.29	79.47	67.50	31.47	32.87	35.55
Receivables Turnover TTM	153.52	7.30	11.62	11.04	3.86	2.95	3.57	4.59	5.41	11.60	11.10	10.27
Per Share Metrics
Diluted EPS TTM	0.82	-0.17	-0.22	-0.28	-0.40	-0.38	-0.41	-0.41	-0.42	-0.44	-0.45	-0.44
Free Cash Flow Per Share TTM	-0.18	-0.21	-0.24	-0.31	-0.31	-0.35	-0.38	-0.39	-0.45	-0.52	-0.52	-0.50
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	101.67%	102.35%	102.53%	103.26%	104.70%
Operating Profit Margin TTM	81.72%	-270.96%	-320.44%	-386.51%	-1,290.88%	-1,236.74%	-1,233.06%	-827.46%	-616.46%	-430.53%	-359.33%	-323.65%
Net Profit Margin TTM	83.95%	-237.88%	-289.45%	-351.92%	-1,195.86%	-1,133.04%	-1,137.64%	-766.20%	-572.81%	-401.57%	-339.32%	-309.89%
Growth Metrics
Net Revenue Growth (1Y)	2,889.93%	128.21%	116.64%	53.23%	-50.69%	-65.98%	-69.69%	-57.25%	-60.80%	-53.51%	-38.19%	-29.47%
Net Income Growth (1Y)	-309.90%	-52.09%	-44.88%	-29.62%	2.94%	-4.02%	1.63%	5.70%	6.22%	4.89%	8.72%	-4.16%
EPS Growth (1Y)	-306.58%	-53.58%	-45.68%	-30.91%	-5.20%	-14.18%	-9.92%	-6.66%	-2.24%	-4.61%	-2.00%	-14.15%
Valuation Metrics
P/E TTM	5.43	-27.51	-20.59	-10.91	-8.69	-8.68	-9.49	-7.54	-6.09	-5.70	-4.51	-5.24
P/B TTM	3.35	12.04	11.25	7.13	8.41	6.23	6.81	4.75	3.95	3.91	2.85	2.84
P/S TTM	4.55	65.44	59.61	38.39	103.95	98.35	107.93	57.75	34.89	22.87	15.29	16.23
Market Cap	871.96M	921.59M	870.68M	591.89M	665.57M	606.94M	727.64M	581.05M	453.11M	414.90M	340.05M	381.95M
Enterprise Value	848.25M	903.59M	848.27M	554.48M	628.49M	570.61M	695.79M	518.26M	410.01M	388.62M	322.52M	354.75M
Calculated Values
Free Cash Flow TTM	-34.36M	-39.64M	-45.36M	-60.28M	-59.03M	-65.03M	-71.92M	-73.00M	-78.92M	-86.94M	-86.78M	-83.74M
Net Debt	-23.71M	-18.01M	-22.41M	-37.41M	-37.08M	-36.33M	-31.85M	-62.79M	-43.10M	-26.29M	-17.53M	-27.20M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-02-04Sale

Owner: Hastings, David C

Title: Chief Financial Officer

Shares: 22,183

Price/Share: $3.28

Value: $72,760.24

Shares Owned: 159,724

Relationship: Officer

Ownership: Direct

2025-02-04Sale

Owner: Mcelhaugh, Michael J.

Title: Interim President & CEO

Shares: 23,790

Price/Share: $3.28

Value: $78,031.20

Shares Owned: 1,481,003

Relationship: Director,Officer

Ownership: Direct

2025-02-04Sale

Owner: Sims, Karen

Title: Chief Medical Officer

Shares: 19,348

Price/Share: $3.28

Value: $63,461.44

Shares Owned: 106,194

Relationship: Officer

Ownership: Direct

2025-02-04Sale

Owner: Naftzger, J. Christopher

Title: General Counsel and CCO

Shares: 11,333

Price/Share: $3.28

Value: $37,172.24

Shares Owned: 86,244

Relationship: Officer

Ownership: Direct

2024-08-14Sale

Owner: Manchester, Keith S

Title: -

Shares: 8,846

Price/Share: $3.69

Value: $32,641.74

Shares Owned: 46,069

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-02-04	Hastings, David C	Officer	Chief Financial Officer	Direct	Sale	22,183	3.28	$72,760.24	159,724	4
2025-02-04	Mcelhaugh, Michael J.	Director,Officer	Interim President & CEO	Direct	Sale	23,790	3.28	$78,031.20	1,481,003	4
2025-02-04	Sims, Karen	Officer	Chief Medical Officer	Direct	Sale	19,348	3.28	$63,461.44	106,194	4
2025-02-04	Naftzger, J. Christopher	Officer	General Counsel and CCO	Direct	Sale	11,333	3.28	$37,172.24	86,244	4
2024-08-14	Manchester, Keith S	Director	-	Direct	Sale	8,846	3.69	$32,641.74	46,069	4
2024-02-02	Mcelhaugh, Michael J.	Director,Officer	Interim President & CEO	Direct	Sale	10,164	2.31	$23,478.84	1,504,793	4
2024-02-02	Hastings, David C	Officer	Chief Financial Officer	Direct	Sale	9,593	2.31	$22,159.83	181,907	4
2024-02-02	Sims, Karen	Officer	Chief Medical Officer	Direct	Sale	4,358	2.31	$10,066.98	125,542	4
2024-02-02	Sofia, Michael J.	Officer	Chief Scientific Officer	Direct	Sale	9,982	2.31	$23,058.42	1,485,121	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

71.55%

Inst. Shares: 138,639,956

Shares Outstanding: 193,768,641

2025-12-31

63.61%

Inst. Shares: 121,879,122

Shares Outstanding: 191,599,600

2025-09-30

61.53%

Inst. Shares: 118,009,887

Shares Outstanding: 191,778,950

2025-06-30

61.33%

Inst. Shares: 117,469,163

Shares Outstanding: 191,551,282

2025-03-31

58.34%

Inst. Shares: 111,254,583

Shares Outstanding: 190,707,085

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	138,639,956	193,768,641	71.55%
2025-12-31	121,879,122	191,599,600	63.61%
2025-09-30	118,009,887	191,778,950	61.53%
2025-06-30	117,469,163	191,551,282	61.33%
2025-03-31	111,254,583	190,707,085	58.34%
2024-12-31	103,227,828	185,608,874	55.62%
2024-09-30	100,253,429	188,997,194	53.04%
2024-06-30	96,085,793	188,041,489	51.10%
2024-03-31	82,694,242	175,625,552	47.09%
2023-12-31	78,071,825	165,960,379	47.04%
2023-09-30	70,317,842	167,512,708	41.98%
2023-06-30	65,262,973	166,063,284	39.30%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Arbutus Biopharma Corp (ABUS) — SEC Financial Statements & Analysis

Arbutus Biopharma Corp (ABUS) is a pharmaceutical preparations company, incorporated in A1. Arbutus Biopharma Corp trades on ABUS: Nasdaq as: ABUS. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Arbutus Biopharma Corp reported a 2889.93% year-over-year revenue growth, a Gross Profit Margin of 101.67% (TTM), a Debt-to-Equity ratio of 0.07x, a Price-to-Sales (P/S) ratio of 4.55x (TTM), a Price-to-Book (P/B) ratio of 3.35 (TTM), at a market cap of $871.96M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 2889.93%
Gross Profit Margin TTM: 101.67%
Debt To Equity: 0.07x
P/S TTM: 4.55x
P/B TTM: 3.35
Market Cap: $871.96M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Arbutus Biopharma Corp in?

Arbutus Biopharma Corp (ABUS) operates in the Pharmaceutical Preparations industry.

What is ABUS's market cap?

Arbutus Biopharma Corp (ABUS) has a market capitalization of $871.96M as of 2026-03-31.

What is ABUS's P/E ratio?

Arbutus Biopharma Corp (ABUS)'s trailing twelve month P/E ratio is 5.43x as of 2026-03-31.

What exchange does ABUS trade on?

Arbutus Biopharma Corp (ABUS) trades on the ABUS: Nasdaq.

Where is Arbutus Biopharma Corp incorporated?

Arbutus Biopharma Corp is incorporated in British Columbia, Canada.

Arbutus Biopharma Corp (ABUS) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.